Belite Bio
BLTE
18 hedge funds and large institutions have $9.91M invested in Belite Bio in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 11 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.46% less ownership
Funds ownership: 0.92% → 0.46% (-0.46%)
18% less funds holding
Funds holding: 22 → 18 (-4)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
44% less capital invested
Capital invested by funds: $17.8M → $9.91M (-$7.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$5.04M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$365K |
| 3 |
HF
HRT Financial
New York
|
+$248K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$185K |
| 5 |
VIA
Virtus Investment Advisers
Hartford,
Connecticut
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$10.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$790K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$702K |
| 4 |
Morgan Stanley
New York
|
-$621K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$446K |
BLTE Hedge Fund Activity: Q1 2025 in Review
18 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q1 2025, worth a combined $9.91M — down 44% from $17.8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BLTE and 7 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $5.04M. The largest seller was Armistice Capital, exiting entirely with an estimated $10.6M sold.
- 18 institutional investors held Belite Bio (BLTE) as of Q1 2025, down from 22 in Q4 2024.
- Funds reported $9.91M of Belite Bio stock for Q1 2025, down 44% quarter-over-quarter.
- 7 funds opened new Belite Bio positions in Q1 2025 and 11 closed out, a net change of -4 holders.
- The largest Belite Bio buyer in Q1 2025 was Alyeska Investment Group, an estimated $5.04M added.
- The largest Belite Bio seller in Q1 2025 was Armistice Capital, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2025.